Processing...
Clinical Trials for Head And Neck Cancer
Search
Search
There are 211 active trials for advanced/metastatic head and neck cancer.
Click on a trial to see more information.
211 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Adults with locally advanced/metastatic EGFR-mutant NSCLC or head and neck squamous cell carcinoma receive dose-escalated single-agent EPI-326. EPI-326 is an investigational tissue-selective bispecific antibody that binds EGFR and ITGB6 to promote internalization and lysosomal degradation of wild-type and mutant EGFR.
ClinicalTrials.gov ID: NCT07462377
TrialFetch AI summary: Adults with metastatic or unresectable locally advanced NSCLC, esophageal squamous cell carcinoma, or cutaneous melanoma after standard therapy or 1–2 prior systemic regimens receive IV PF-08046033 in 21-day cycles. PF-08046033 is an investigational GPNMB-directed antibody-drug conjugate delivering auristatin S to GPNMB-expressing tumor cells, with dose escalation followed by tumor-specific expansion cohorts.
ClinicalTrials.gov ID: NCT07519655
TrialFetch AI summary: Patients with ECOG 0–2 and measurable, unresectable locally advanced or metastatic solid tumors, including colorectal cancer, NSCLC, breast cancer, and upper GI adenocarcinomas; expansion focuses on refractory colorectal cancer and NSCLC. All receive IV IM-1617, an antibody–drug conjugate targeting an undisclosed receptor tyrosine kinase and delivering the HC74 topoisomerase-I inhibitor payload.
ClinicalTrials.gov ID: NCT07578571
TrialFetch AI summary: Adults with refractory unresectable or metastatic solid tumors and an accessible injectable lesion, with expansion cohorts in cutaneous squamous-cell carcinoma, melanoma, head and neck squamous-cell carcinoma, NSCLC, and triple-negative breast cancer. Patients receive intratumoral N17350 every 2 weeks, a recombinant mutant porcine pancreatic elastase targeting the neutrophil elastase/ELANE pathway and designed to induce immunogenic tumor-cell death.
ClinicalTrials.gov ID: NCT07339176
TrialFetch AI summary: Adults with unresectable or metastatic solid tumors after prior immune-checkpoint or related T-cell-directed therapy and appropriate standard therapy may receive oral ARV-6723 alone or with pembrolizumab. ARV-6723 is an investigational PROTAC that degrades HPK1/MAP4K1 to enhance antitumor immune signaling; later cohorts may include investigator-selected standard of care.
ClinicalTrials.gov ID: NCT07749586
TrialFetch AI summary: Adults with unresectable advanced solid tumors that have progressed after at least one systemic therapy receive ADCE-T02 monotherapy, with expansion cohorts for head and neck squamous cell carcinoma and pancreatic ductal adenocarcinoma. ADCE-T02 is a tissue factor–targeted antibody-drug conjugate that delivers the topoisomerase-I inhibitor exatecan.
ClinicalTrials.gov ID: NCT06597721
TrialFetch AI summary: Adults with locally advanced unresectable or metastatic HNSCC, ESCC, mCRPC, squamous NSCLC, or SCLC receive ASP388B, an investigational antibody–drug conjugate with an undisclosed target, as monotherapy. Previously untreated recurrent/metastatic HNSCC or ESCC cohorts receive ASP388B with pembrolizumab and platinum/5-fluorouracil chemotherapy.
ClinicalTrials.gov ID: NCT07730021
TrialFetch AI summary: Adults with relapsed or refractory advanced pancreatic, colorectal, biliary tract, head and neck squamous cell, esophageal, or gastric cancer receive the NTSR1-targeted imaging agent SKL35502. Those with tumor uptake on imaging may receive SKL35501, an actinium-225–linked NTSR1-targeted radiopharmaceutical designed to deliver alpha radiation to tumor cells.
ClinicalTrials.gov ID: NCT07812805
TrialFetch AI summary: Adults with ECOG 0–1 and unresectable advanced, metastatic, or recurrent solid tumors lacking appropriate approved treatment options, including NSCLC and other squamous cancers, receive intravenous IDP-001. This investigational bispecific antibody–drug conjugate targets EGFR and CDCP1 and delivers the microtubule-disrupting payload monomethyl auristatin E.
ClinicalTrials.gov ID: NCT07602842
TrialFetch AI summary: Adults with previously treated advanced or metastatic solid tumors, ECOG 0–1, measurable disease, and a biopsiable tumor receive intravenous or subcutaneous ST-067, alone, after obinutuzumab pretreatment, or with pembrolizumab. ST-067 is an engineered IL-18 that activates the IL-18 receptor while resisting neutralization by IL-18 binding protein; expansion cohorts focus on melanoma, renal cell, triple-negative breast, non-small cell lung, head and neck squamous cell, and MSI-high cancers.
ClinicalTrials.gov ID: NCT04787042